Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

20132,659 citationsJournal Articlebronze Open Access

Authors

William J. Sandborn · University of California San Diego

Brian G. Feagan · Western University

Paul Rutgeerts

Stephen B. Hanauer · University of Chicago

Jean‐Frédéric Colombel · Centre Hospitalier Universitaire de Lille

Bruce E. Sands · Icahn School of Medicine at Mount Sinai

Milan Lukáš · General University Hospital in Prague

Abstract

Among patients with moderately to severely active Crohn's disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a clinical response to induction therapy. (Funded by Janssen Research and Development; ClinicalTrials.gov numbers, NCT01369329 , NCT01369342 , and NCT01369355 .).

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Autoimmune and Inflammatory Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 8, pp. 711-721

DOI: 10.1056/nejmoa1215739

Field-Weighted Citation Impact: 94.04